Glutaminase Inhibitors—Do They Have a Role in the Treatment of Metastatic Clear-Cell Renal Cell Carcinoma?-Reference-Cited by-同舟云学术

Glutaminase Inhibitors—Do They Have a Role in the Treatment of Metastatic Clear-Cell Renal Cell Carcinoma?

Published:2022-10-01 Issue:10 Volume:8 Page:1418
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Brown Janet E.¹

Affiliation:

1. Department of Oncology and Metabolism, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2795983/jamaoncology_brown_2022_ic_220013_1666196345.86018.pdf

Reference4 articles.

1. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial.;Tannir;JAMA Oncol

2. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase 2 ENTRATA trial.;Lee;Clin Cancer Res

3. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.;Motzer;Cancer,2022

4. Study CB-839 in combination with nivolumab in patients with melanoma, clear cell renal cell carcinoma (ccRCC) and non-small cell lung cancer (NSCLC). ClinicalTrials.gov identifier: NCT02771626. Updated August 19, 2021. Accessed July 27, 2022. https://clinicaltrials.gov/ct2/show/NCT02771626

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Core NRF2 Gene Set Defined Through Comprehensive Transcriptomic Analysis Predicts Selective Drug Resistance and Poor Multicancer Prognosis;Antioxidants & Redox Signaling;2024-08-08

2. A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosis;2023-04-21

3. Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group;European Journal of Medicinal Chemistry;2023-01